Amgen To Rapidly Move Olpasiran Into Phase III For Lp(a) Reduction

The siRNA drug demonstrated a significant reduction in lipoprotein(a) from baseline of up to or greater than 90% for the majority of doses in a Phase II trial; Novartis has a potential first-to-market advantage.

chess piece advancing
Amgen is advancing olpasiran into Phase III • Source: Shutterstock

Amgen, Inc. plans to move quickly into a Phase III development program with its cardiovascular drug candidate olpasiran, a small interfering RNA drug targeting lipoprotein(a), following a successful Phase II study. There are no approved drugs to lower Lp(a) levels, but Amgen is behind rival Novartis AG in the effort to bring the first to market; Novartis has the Lp(a)-targeting drug pelacarsen in Phase III development.

Amgen said it hopes to advance olpasiran quickly. "In parallel to the Phase II program, we've been planning a Phase...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.